CBD assessment refers to the evaluation of the common bile duct (CBD), a crucial component of the biliary system responsible for transporting bile from the liver and gallbladder to the small intestine. This assessment is typically performed to diagnose various conditions affecting the CBD, such as stones, strictures, tumors, or inflammation. Imaging modalities such as ultrasound, magnetic resonance cholangiopancreatography (MRCP), or endoscopic retrograde cholangiopancreatography (ERCP) may be utilized to assess the CBD's anatomy and detect abnormalities. Additionally, blood tests to assess liver function and levels of bilirubin may provide valuable information about CBD function and potential obstruction. Depending on the findings, further diagnostic procedures such as endoscopic ultrasound (EUS) or biopsy may be recommended to obtain more detailed information about CBD pathology. CBD assessment is crucial for diagnosing and managing various biliary tract disorders, guiding treatment decisions, and improving patient outcomes.